Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entera Bio's Operating Income for the
three
months ended in Jun. 2026 was €-3.96 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was €-12.39 Mil.
Operating Margin % is calculated as Operating Income divided by its Revenue. Entera Bio's Operating Income for the
three
months ended in Jun. 2026 was €-3.96 Mil. Entera Bio's Revenue for the
three
months ended in Jun. 2026 was €0.00 Mil. Therefore, Entera Bio's Operating Margin % for the quarter that ended in Jun. 2026 was %.
Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Entera Bio's annualizedROC % for the quarter that ended in Jun. 2026 was -246.27%.
Entera Bio's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -269.64%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.
Be Aware
Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Entera Bio Operating Income Related Terms
Entera Bio Operating Income Historical Data
* Premium members only.
The historical data trend for Entera Bio's Operating Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.
Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entera Bio (STU:5DT) has a Operating Income of €-12.39 Mil as of Jun. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Entera Bio and its competitors.
Is Entera Bio's Operating Income too high?
Entera Bio's current Operating Income is €-12.39 Mil. Overall, Entera Bio has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's Operating Income compare to ICCC and BDTX?
Entera Bio's Operating Income of €-12.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Biotechnology company?
A good Operating Income depends on the Biotechnology industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Entera Bio and its competitors. Entera Bio's current Operating Income is €-12.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Based on GuruFocus' analysis, Entera Bio (STU:5DT) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.21, compared to a current price of €2.46 — trading 1071.4% above its estimated fair value. The current Operating Income is €-12.39 Mil. Entera Bio's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Entera Bio (STU:5DT), the current Operating Income is €-12.39 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Entera Bio (STU:5DT) Overvalued in 2026?
Based on GuruFocus' analysis, Entera Bio stock appears to be overvalued.
The current stock price of €2.46 is trading 1071.4% above its estimated GF Value™ of €0.21.
GuruFocus considers Entera Bio to be Significantly Overvalued.
Key valuation signals for STU:5DT:
Operating Income: €-12.39 Mil
GF Value™: €0.21 vs. price of €2.46 (1071.4% above fair value)
No single metric tells the full story. See the STU:5DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
37GF Score
Get the complete analysis for STU:5DT
Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5DT has been successfully added to your 
